Connect Biopharma Holdings Ltd - ADR Stock

$0.58

8.39% today

Nasdaq, Apr 03, 06:44 pm CET

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Connect Biopharma Holdings Ltd - ADR Stock price

$0.63

-16.37 96.29% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

+0.06 10.21%

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$34.90m
Enterprise Value	$-58.63m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	2.41
EV/Sales (TTM) EV/Sales	-2.25
P/S ratio (TTM) P/S ratio	1.34
P/B ratio (TTM) P/B ratio	0.38
Revenue (TTM) Revenue	$26.03m
EBIT (operating result TTM) EBIT	$-22.39m
Free Cash Flow (TTM) Free Cash Flow	$-24.30m
EPS (TTM) EPS	$-0.28
P/E forward	negative
Short interest	0.03%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Connect Biopharma Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Connect Biopharma Holdings Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Dec '24		+/- %
Revenue	26 26	- 100%
- Direct Costs	0.66 0.66	- 3%
Gross Profit	25 25	- 97%
- Selling and Administrative Expenses	18 18	- 69%
- Research and Development Expense	29 29	- 112%
EBITDA	-22 -22	- -83%
- Depreciation and Amortization	0.66 0.66	- 3%
EBIT (Operating Income) EBIT	-22 -22	- -86%
Net Profit	-16 -16	- -60%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Connect Biopharma Holdings Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

2 days ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transfo...

Neutral

GlobeNewsWire

●

3 days ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademikibart for 24 weeks, the mean difference from placebo in forced expiratory volume was +420 mL, amongst the largest increases reported for a biologic – SAN DIEGO,...

Neutral

GlobeNewsWire

●

3 days ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise Unveiled rapid clinical development program for rademikibart initially targeting acute care in asthma and COPD; expect to initiate parallel Phase 2 trials in 2Q 2025 with data expected in 2H 2026 Stro...

More Connect Biopharma Holdings Ltd - ADR News

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Head office	Cayman Islands
CEO	Barry Quart
Employees	62
Founded	2015
Website	www.connectbiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now